Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents-Reference-Cited by-同舟云学术

Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents

Published:2013-09 Issue:2 Volume:337 Page:218-225
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Cheng An Ning,Jiang Shih Sheng,Fan Chi-Chen,Lo Yu-Kang,Kuo Chan-Yen,Chen Chung-Hsing,Liu Ying-Lan,Lee Chun-Chung,Chen Wei-Shone,Huang Tze-Sing,Wang Tao-Yeuan,Lee Alan Yueh-Luen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells?;Labib;Genes Dev.,2010

2. Initiating DNA synthesis: from recruiting to activating the MCM complex;Lei;J Cell Sci,2001

3. A Cdc7p-Dbf4p protein kinase activity is conserved from yeast to humans;Johnston;Prog. Cell Cycle Res.,2000

4. The Cdc7 protein kinase is required for origin firing during S phase;Bousset;Genes Dev.,1998

5. Cdc7 kinases (DDKs) and checkpoint responses: lessons from two yeasts;Duncker;Mutat. Res.,2003

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorcin in Cancer Development and Chemotherapeutic Drug Resistance;Cancers;2024-08-09

2. Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study;Cancer Research Communications;2022-11-14

3. Degree of stemness predicts micro-environmental response and clinical outcomes of diffuse large B-cell lymphoma and identifies a potential targeted therapy;Frontiers in Immunology;2022-11-08

4. Quantitative Phosphoproteomics and Acetylomics of Safranal Anticancer Effects in Triple-Negative Breast Cancer Cells;Journal of Proteome Research;2022-09-29

5. Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach;Cancers;2022-09-27